Heidelberg Pharma Investor Relations Material
Latest events
Status Update
Heidelberg Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Heidelberg Pharma AG
Access all reports
Heidelberg Pharma is a biopharmaceutical company that focuses on oncology and antibody targeted amanitin conjugates (ATAC). Their innovations are based on cell immunotherapy and the drug amanitin conjugates (ATAC). The tumor cells are attacked by immune cells, which recognize the amanitin antigen as a foreign body. This way the treatment causes no mutilation of healthy tissue.
Key slides for Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Q4 2024
Heidelberg Pharma AG
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
HPHA
Country
🇩🇪 Germany